Put the 9-Phase Framework to work for your market Whether you need a one-off market sizing or an always-on intelligence partnership, our analysts can scope the right engagement in a 30-minute call
Kailera Therapeutics, Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions, Press Release, October 1, 2024
Current conservative interventions for OA, such as physical workouts and oral nonsteroidal anti-inflammatory drugs (NSAIDs), seek to mitigate the disease's development during its early to mid-stages [11]
GLP-1 medications, or glucagon-like peptide-1 receptor agonists, treat type 2 diabetes and, in some cases, obesity
Building muscle requires extra energy (and protein) so that your body can create new tissue
irritans increased following zinc ion treatment